1. 51st Annual Scientific Session for the LIFE Investigators
The LIFE Trial
Losartan Intervention For Endpoint reduction in hypertension study (LIFE)
Presented at the American College of Cardiology
51st Annual Scientific Session
Atlanta, GA
Dr Björn Dahlöf
for the LIFE Investigators

2. LIFE: Study Design Losartan Atenolol Angiotensin II antagonist
Patients with hypertension (blood pressure / mm Hg)
and left ventricular hypertrophy
Losartan
Angiotensin II antagonist
Dose titrated to BP <140/90 mm Hg
(n=4,605)
Atenolol
Beta-blocker
Dose titrated to BP <140/90 mm Hg
(n=4,588)
Followed for >4 years - Mean follow-up 4.8 years
Cardiovascular death, MI, stroke

3. LIFE: Primary Composite Endpoint
Composite of CV Death / MI / Stroke
P=0.021
Adjusted Hazard Ratio = 0.87
Rate 23.8/1,000
patient yrs
Rate 27.9/1,000
patient yrs
n=508
n=588
Losartan
Atenolol

4. LIFE: Individual Endpoint Results
Cardiovascular Death
Myocardial Infarction
Stroke
P=0.206
P=0.491
P=0.001
Adjusted HR 0.89
Adjusted HR 1.07
Adjusted HR 0.75
Losartan
Atenolol
Losartan
Atenolol
Losartan
Atenolol

5. LIFE: New-onset diabetes
P=0.001
Adjusted Hazard Ratio = 0.75
Rate 13.0/1,000
patient yrs
Rate 17.4/1,000
patient yrs
n=241
n=319
Losartan
Atenolol